

References

- Amodio, V., Yaeger, R., Arcella, P., Cancelliere, C., Lamba, S., Lorenzato, A., Arena, S., Montone, M., Mussolin, B., Bian, Y., Whaley, A., Pinnelli, M., Murciano-Goroff, Y. R., Vakiani, E., Valeri, N., Liao, W.-L., Bhalkikar, A., Thyparambil, S., Zhao, H.-Y., ... Misale, S. (2020). EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer. *Cancer Discovery*, 10(8), 1129–1139. <https://doi.org/10.1158/2159-8290.CD-20-0187>
- Angelopoulos, P. A., Passaro, A., Attili, I., Trillo Aliaga, P., Corvaja, C., Spitaleri, G., Battaiotto, E., Del Signore, E., Curigliano, G., & de Marinis, F. (2025). Management of MET-Driven Resistance to Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer. *Genes*, 16(7), 772. <https://doi.org/10.3390/genes16070772>
- Attili, I., Fabrizio, F. P., & Marinis, F. de. (2025). Co-Occurring Genomic Alterations in NSCLC: Making Order into a Crowded List. *Cancers*, 17(14), 2388. <https://doi.org/10.3390/cancers17142388>
- Bell, C. C., & Gilan, O. (2020). Principles and mechanisms of non-genetic resistance in cancer. *British Journal of Cancer*, 122(4), 465–472. <https://doi.org/10.1038/s41416-019-0648-6>
- Belloni, A., Pugnali, A., Rippo, M. R., Di Valerio, S., Giordani, C., Procopio, A. D., & Bronte, G. (2024). The cell line models to study tyrosine kinase inhibitors in non-small cell lung cancer with mutations in the epidermal growth factor receptor: A scoping review. *Critical Reviews in Oncology/Hematology*, 194, 104246. <https://doi.org/10.1016/j.critrevonc.2023.104246>
- Blechter, B., Hsiung, C. A., Wang, X., Zhang, H., Seow, W. J., Shi, J., Chatterjee, N., Kim, H. N., Wong, M. P., Hong, Y.-C., Wong, J. Y. Y., Dai, J., Hosgood, H. D., Wang, Z., Chang, I.-S., Choi, J., Wang, J., Song, M., Hu, W., ... Lan, Q. (2024). Polygenic risk score and lung adenocarcinoma risk among never-smokers by EGFR mutation status-a brief report. *Journal of Thoracic Oncology*. <https://doi.org/10.1016/j.jtho.2024.11.019>

- Boumahdi, S., & de Sauvage, F. J. (2020). The great escape: tumour cell plasticity in resistance to targeted therapy. *Nature Reviews Drug Discovery*, 19(1), 39–56. <https://doi.org/10.1038/s41573-019-0044-1>
- Bronte, G., Belloni, A., Calabrò, L., & Crinò, L. (2024). The great need to overcome osimertinib resistance in advanced non-small cell lung cancer: from combination strategies to fourth-generation tyrosine kinase inhibitors. *Frontiers in Oncology*, 13. <https://doi.org/10.3389/fonc.2023.1308460>
- Brown, B. P., Zhang, Y.-K., Kim, S., Finneran, P., Yan, Y., Du, Z., Kim, J., Abigail Leigh Hartzler, LeNoue-Newton, M. L., Smith, A. W., Meiler, J., & Lovly, C. M. (2022). Allele-specific activation, enzyme kinetics, and inhibitor sensitivities of EGFR exon 19 deletion mutations in lung cancer. *Proceedings of the National Academy of Sciences of the United States of America*, 119(30). <https://doi.org/10.1073/pnas.2206588119>
- Burgess, J. T., Rose, M., Boucher, D., Plowman, J., Molloy, C., Fisher, M., O’Leary, C., Richard, D. J., O’Byrne, K. J., & Bolderson, E. (2020). The Therapeutic Potential of DNA Damage Repair Pathways and Genomic Stability in Lung Cancer. *Frontiers in Oncology*, 10. <https://doi.org/10.3389/fonc.2020.01256>
- Burkhardt, D., Perez, B., Lock, J. G., Krishnaswamy, S., & Chaffer, C. L. (2022). Mapping Phenotypic Plasticity upon the Cancer Cell State Landscape Using Manifold Learning. *Cancer Discovery*, 12(8), 1847–1859. <https://doi.org/10.1158/2159-8290.cd-21-0282>
- Burt, J. R., Qaqish, N., Stoddard, G., Amani Jridi, Anderson, P. S., Woods, L., Newman, A., Carter, M. R., Reham Ellessy, Chamberlin, J., & Ismail Kabakus. (2025). Non-small cell lung cancer in ever-smokers vs never-smokers. *BMC Medicine*, 23(1). <https://doi.org/10.1186/s12916-024-03844-8>
- Cabanos, H. F., & Hata, A. N. (2021). Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer. *Cancers*, 13(11), 2666. <https://doi.org/10.3390/cancers13112666>

- Cali, E., Miao, E., Tang, K., Chiu, G., & Cheng, H. (2023). Lung Cancer in Never Smokers: Delving into Epidemiology, Genomic and Immune Landscape, Prognosis, Treatment, and Screening. *Lung*, 201(6), 521–529. <https://doi.org/10.1007/s00408-023-00661-3>
- Callahan, V., Hawks, S. A., Crawford, M. A., Lehman, C. W., Morrison, H. A., Ivester, H. M., Akhrymuk, I. V., Boghdeh, N., Flor, R., Finkielstein, C. V., Allen, I. C., Weger-Lucarelli, J., Duggal, N. K., Hughes, M. A., & Kehn-Hall, K. (2021, June 3). *The Pro-Inflammatory Chemokines CXCL9, CXCL10 and CXCL11 Are Upregulated Following SARS-CoV-2 Infection in an AKT-Dependent Manner*. Vt.Edu; MDPI. <https://vtechworks.lib.vt.edu/items/f6f7a785-1701-49cf-b80d-e641a5428b95>
- Camolotto, S. A., Pattabiraman, S., Mosbrugger, T. L., Jones, A., Belova, V. K., Orstad, G., Streiff, M., Salmond, L., Stubben, C., Kaestner, K. H., & Snyder, E. L. (2018). FoxA1 and FoxA2 drive gastric differentiation and suppress squamous identity in NKX2-1-negative lung cancer. *eLife*, 7, e38579. <https://doi.org/10.7554/eLife.38579>
- Catania, F., Ujvari, B., Roche, B., Capp, J.-P., & Thomas, F. (2021). Bridging Tumorigenesis and Therapy Resistance With a Non-Darwinian and Non-Lamarckian Mechanism of Adaptive Evolution. *Frontiers in Oncology*, 11. <https://doi.org/10.3389/fonc.2021.732081>
- Chamorro, D. F., Cardona, A. F., Rodríguez, J., Ruiz-Patiño, A., Arrieta, O., Moreno-Pérez, D. A., Rojas, L., Zatarain-Barrón, Z. L., Ardila, D. V., Viola, L., Recondo, G., Blaquier, J. B., Martín, C., Ruez, L., Samtani, S., Ordóñez-Reyes, C., Garcia-Robledo, J. E., Corrales, L., Sotelo, C., ... Rosell, R. (2023). Genomic Landscape of Primary Resistance to Osimertinib Among Hispanic Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Results of an Observational Longitudinal Cohort Study. *Targeted Oncology*, 18(3), 425–440. <https://doi.org/10.1007/s11523-023-00955-9>
- Chao, C. H.-Y., & Di, Y. P. (2025). Etiology and current advances in treating KRAS-mutated lung cancer. *Chinese Medical Journal Pulmonary and Critical Care Medicine*. <https://doi.org/10.1016/j.pccm.2025.08.001>

- Chavez-Dominguez, R., Aguilar-Cazares, D., Perez-Medina, M., Avila-Rios, S., Soto-Nava, M., Mendez-Tenorio, A., Islas-Vazquez, L., Benito-Lopez, J. J., Galicia-Velasco, M., & Lopez-Gonzalez, J. S. (2023). Transcriptional signature of early cisplatin drug-tolerant persister cells in lung adenocarcinoma. *Frontiers in Oncology*, 13. <https://doi.org/10.3389/fonc.2023.1208403>
- Chen, J. A., & Riess, J. W. (2020). Advances in targeting acquired resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors. *Journal of Thoracic Disease*, 12(5), 2859–2876. <https://doi.org/10.21037/jtd.2019.08.32>
- Chen, M., Mainardi, S., Liefink, C., Velds, A., Rink, I. de, Yang, C., Kuiken, H. J., Morris, B., Edwards, F., Jochems, F., Telling, O. van, Boei, M., Proost, N., Jansen, R. A., Qin, S., Jin, H., van, Schepers, A., Venkatesan, S., ... Bernards, R. (2024). Targeting of vulnerabilities of drug-tolerant persisters identified through functional genetics delays tumor relapse. *Cell Reports Medicine*, 5(3), 101471–101471. <https://doi.org/10.1016/j.xcrm.2024.101471>
- Chen, S., Chen, H., Dong, P., Wang, Y., Huang, J., & Wang, J. (2026). Mechanistic insights and clinical implications of the S100 protein family in breast cancer. *Biomedicine & Pharmacotherapy*, 198, 119358. <https://doi.org/10.1016/j.biopha.2026.119358>
- Chen, X., Stauffer, S., Chen, Y., & Dong, J. (2016). Ajuba Phosphorylation by CDK1 Promotes Cell Proliferation and Tumorigenesis. *Journal of Biological Chemistry*, 291(28), 14761–14772. <https://doi.org/10.1074/jbc.m116.722751>
- Chen, Y., Toth, R., Chocarro, S., Weichenhan, D., Hey, J., Lutsik, P., Sawall, S., Stathopoulos, G. T., Plass, C., & Sotillo, R. (2022). Club cells employ regeneration mechanisms during lung tumorigenesis. *Nature Communications*, 13(1), 4557. <https://doi.org/10.1038/s41467-022-32052-2>
- Cheng, E. S., Weber, M., Steinberg, J., & Qin Yu, X. (2021). Lung cancer risk in never-smokers: An overview of environmental and genetic factors. *Chinese Journal of Cancer Research*, 33(5), 548–562. <https://doi.org/10.21147/j.issn.1000-9604.2021.05.02>

- Cheng, Y., He, Y., Li, W., Zhang, H., Zhou, Q., Wang, B., Liu, C., Walding, A., Saggese, M., Huang, X., Fan, M., Wang, J., & Ramalingam, S. S. (2021). Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study. *Targeted Oncology*, 16(2), 165–176. <https://doi.org/10.1007/s11523-021-00794-6>
- Chhouri, H., Alexandre, D., & Grumolato, L. (2023). Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer. *Cancers*, 15(2), 504. <https://doi.org/10.3390/cancers15020504>
- Chmielecki, J., Gray, J. E., Cheng, Y., Ohe, Y., Imamura, F., Cho, B. C., Lin, M.-C., Majem, M., Shah, R., Rukazenkov, Y., Todd, A., Markovets, A., Barrett, J. C., Hartmaier, R. J., & Ramalingam, S. S. (2023). Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer. *Nature Communications*, 14(1). <https://doi.org/10.1038/s41467-023-35961-y>
- Cho, B. C., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Sriuranpong, V., Imamura, F., Nogami, N., Kurata, T., Okamoto, I., Zhou, C., Cheng, Y., Cho, E. K., Voon, P. J., Lee, J.-S., Mann, H., Saggese, M., Reungwetwattana, T., Ramalingam, S. S., & Ohe, Y. (2019). Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset. *Journal of Thoracic Oncology*, 14(1), 99–106. <https://doi.org/10.1016/j.jtho.2018.09.004>
- Chou, Y.-T., Allegakoen, P., & Bivona, T. G. (2024). Targeting Minimal Residual Disease. *Annual Review of Cancer Biology*. <https://doi.org/10.1146/annurev-cancerbio-070924-120742>
- Coleman, N., Hong, L., Zhang, J., Heymach, J., Hong, D., & Le, X. (2021). Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer. *ESMO Open*, 6(6), 100319. <https://doi.org/10.1016/j.esmoop.2021.100319>

- Cooper, A. J., Sequist, L. V., & Lin, J. J. (2022). Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management. *Nature Reviews Clinical Oncology*, 19(8), 499–514. <https://doi.org/10.1038/s41571-022-00639-9>
- Corrales, L., Rosell, R., Cardona, A. F., Martín, C., Zatarain-Barrón, Z. L., & Arrieta, O. (2020). Lung cancer in never smokers: The role of different risk factors other than tobacco smoking. *Critical Reviews in Oncology/Hematology*, 148(4), 102895. <https://doi.org/10.1016/j.critrevonc.2020.102895>
- Corvaja, C., Passaro, A., Attili, I., Aliaga, P. T., Spitaleri, G., Signore, E. Del, & Marinis, F. de. (2024). Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: Bridging biological insights and therapeutic development. *Cancer Treatment Reviews*, 130, 102824–102824. <https://doi.org/10.1016/j.ctrv.2024.102824>
- Criscione, S. W., Martin, M. J., Oien, D. B., Gorthi, A., Miragaia, R. J., Zhang, J., Chen, H., Karl, D. L., Mendler, K., Markovets, A., Gargica, S., Delpuech, O., Dry, J. R., Grondine, M., Hattersley, M. M., Urosevic, J., Floc'h, N., Drew, L., Yao, Y., & Smith, P. D. (2022). The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells. *Npj Precision Oncology*, 6(1). <https://doi.org/10.1038/s41698-022-00337-w>
- De Conti, G., Dias, M. H., & Bernards, R. (2021). Fighting Drug Resistance through the Targeting of Drug-Tolerant Persister Cells. *Cancers*, 13(5), 1118. <https://doi.org/10.3390/cancers13051118>
- De Guzman, R. B. (2025). Early-onset lung cancer in Asia: a narrative review. *Frontiers in Oncology*, 15. <https://doi.org/10.3389/fonc.2025.1631443>
- Delahaye, C., Figarol, S., Pradines, A., Favre, G., Mazières, J., & Calvayrac, O. (2022). Early Steps of Resistance to Targeted Therapies in Non-Small-Cell Lung Cancer. *Cancers*, 14(11), 2613–2613. <https://doi.org/10.3390/cancers14112613>
- Dhanyamraju, P. K., Schell, T. D., Amin, S., & Robertson, G. P. (2022). Drug-Tolerant Persister Cells in Cancer Therapy Resistance. *Cancer Research*, 82(14), 2503–2514. <https://doi.org/10.1158/0008-5472.can-21-3844>

- Du, X., Yang, B., An, Q., Assaraf, Y. G., Cao, X., & Xia, J. (2021). Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors. *The Innovation*, 2(2), 100103. <https://doi.org/10.1016/j.xinn.2021.100103>
- Duval, K., Grover, H., Han, L.-H., Mou, Y., Pegoraro, A. F., Fredberg, J., & Chen, Z. (2017). Modeling Physiological Events in 2D vs. 3D Cell Culture. *Physiology*, 32(4), 266–277. <https://doi.org/10.1152/physiol.00036.2016>
- Eide, I. J. Z., Helland, Å., Ekman, S., Mellemgaard, A., Hansen, K. H., Cicenäs, S., Koivunen, J., Grønberg, B. H., & Brustugun, O. T. (2020). Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study). *Lung Cancer*, 143, 27–35. <https://doi.org/10.1016/j.lungcan.2020.03.009>
- Engelbrecht, E., Kooistra, T., Burg, N., Hariri, L., Nguyen, T., Brazee, P., Hla, T., Gochuico, B. R., & Knipe, R. S. (2025). Ectopic Expansion of Pulmonary Vasculature in Fibrotic Lung Disease and Lung Adenocarcinoma Marked by Proangiogenic COL15A1+ Endothelial Cells. *Pulmonary Circulation*, 15(2). <https://doi.org/10.1002/pul2.70102>
- Espinoza, A. S., McVicar, R. N., Finlay, D., Murad, R., Vuori, K., Grimmig, B. A., Bush, A., Smith, E., Mandel-Clausen, T., McGee, H. M., Snyder, E. Y., & Leibel, S. L. (2023). *The effects of cell-cell orientation in modeling the hallmarks of lung cancer in vitro*. <https://doi.org/10.1101/2023.12.30.573475>
- Fang, Z., Han, X., Chen, Y., Tong, X., Xue, Y., Yao, S., Tang, S., Pan, Y., Sun, Y., Wang, X., Jin, Y., Chen, H., Hu, L., Hui, L., Li, L., Chen, L., & Ji, H. (2023). Oxidative stress-triggered Wnt signaling perturbation characterizes the tipping point of lung adenocarcinoma transdifferentiation. *Signal Transduction and Targeted Therapy*, 8(1), 16. <https://doi.org/10.1038/s41392022012270>
- Fernando, Gentile, C., Feng, W. W., Silva, S. J., Sankar, A., Exposito, F., Cai, W. L., Mary Ann Melnick, Robles-Oteiza, C., Hinkley, M. M., Tsai, J. A., Hartley, A.-V., Wei, J., Wurtz, A., Li, F., Toki, M. I., Rimm, D. L., Homer, R., Wilen, C. B., ... Politi, K. A. (2023). Mammalian SWI/SNF chromatin

- remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer. *Cancer Cell*, 41(8), 1516–1534.e9. <https://doi.org/10.1016/j.ccell.2023.07.005>
- Ferone, G., Song, J., Sutherland, K. D, Bhaskaran, R., Monkhorst, K., Lambooi, J., Proost, N., Gargiulo, G., & Berns, A. (2016). SOX2 Is the Determining Oncogenic Switch in Promoting Lung Squamous Cell Carcinoma from Different Cells of Origin. *Cancer Cell*, 30(4), 519–532. <https://doi.org/10.1016/j.ccell.2016.09.001>
- Ferro, A., Marinato, G. M., Mulargiu, C., Marino, M., Pasello, G., Guarneri, V., & Bonanno, L. (2024). The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies. *Critical Reviews in Oncology/Hematology*, 196, 104295–104295. <https://doi.org/10.1016/j.critrevonc.2024.104295>
- Fu, K., Xie, F., Wang, F., & Fu, L. (2022). Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. *Journal of Hematology & Oncology*, 15(1). <https://doi.org/10.1186/s13045-022-01391-4>
- Gan, J., Huang, Y., Liao, J., Pang, L., & Fang, W. (2021). HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy. *OncoTargets and Therapy*, Volume 14, 5297–5307. <https://doi.org/10.2147/ott.s335217>
- Gao, Y., Zhang, W., Han, X., Li, F., Wang, X., Wang, R., Fang, Z., Tong, X., Yao, S., Li, F., Feng, Y., Sun, Y., Hou, Y., Yang, Z., Guan, K., Chen, H., Zhang, L., & Ji, H. (2014). YAP inhibits squamous transdifferentiation of Lkb1deficient lung adenocarcinoma through ZEB2dependent DNp63 repression. *Nature Communications*, 5(1), 4629. <https://doi.org/10.1038/ncomms5629>
- Garrido, J., Bernal, Y., González, E., Blanco, A., Sepúlveda-Hermosilla, G., Freire, M., Oróstica, K., Rivas, S., Marcelain, K., Owen, G., Ibañez, C., Corvalan, A., Garrido, M., Assar, R., Lizana, R., Cáceres-Molina, J., Ampuero, D., Ramos, L., Pérez, P., ... Armisen, R. (2024). Beyond tobacco:

- genomic disparities in lung cancer between smokers and never-smokers. *BMC Cancer*, 24(1).
<https://doi.org/10.1186/s12885-024-12737-1>
- Ghorbian, S. (2025). Cancer cell plasticity and therapeutic resistance: mechanisms, crosstalk, and translational perspectives. *Hereditas*, 162(1). <https://doi.org/10.1186/s41065-025-00564-8>
- Gini, B., Gui, P., Wu, W., Lucas Kerr, D., Tan, L., Barbosa, D., Olivas, V., Allegakoen, P., Gomez, C., Halliday, P. R., Elmes, S., Steri, V., Chakrabarti, T., Bivona, T. G., & Blakely, C. M. (2024). *CDK4 or CDK6 upregulation induces DNA replication stress and genomic instability to cause EGFR targeted therapy resistance in lung cancer*. <https://doi.org/10.1101/2024.03.12.584638>
- Gomatou, G., Syrigos, N., & Kotteas, E. (2023). Osimertinib Resistance: Molecular Mechanisms and Emerging Treatment Options. *Cancers*, 15(3), 841. <https://doi.org/10.3390/cancers15030841>
- Gu, Y., He, H., Qiao, S., Shao, Y., Wang, L., Zhang, Z., Zhang, L., & Zhou, F. (2025). EGFR: New Insights on Its Activation and Mutation in Tumor and Tumor Immunotherapy. *Advanced Science*.
<https://doi.org/10.1002/advs.202505785>
- Guo, W., Shao, F., Sun, S., Song, P., Guo, L., Xue, X., Zhang, G., Zhang, H., Gao, Y., Qiu, B., Tan, F., Gao, S., & He, J. (2020). Loss of SUSD2 expression correlates with poor prognosis in patients with surgically resected lung adenocarcinoma. *Journal of Cancer*, 11(7), 1648–1656.
<https://doi.org/10.7150/jca.39319>
- Hajdu, T., Váradi, T., Rebenku, I., Kovács, T., Szöllösi, J., & Nagy, P. (2020). Comprehensive Model for Epidermal Growth Factor Receptor Ligand Binding Involving Conformational States of the Extracellular and the Kinase Domains. *Frontiers in Cell and Developmental Biology*, 8.
<https://doi.org/10.3389/fcell.2020.00776>
- Han, P.-F., Che, X.-Da, Li, H.-Z., Gao, Y.-Y., Wei, X.-C., & Li, P.-C. (2020). Annexin A1 involved in the regulation of inflammation and cell signaling pathways. *Chinese Journal of Traumatology*, 23(2), 96–101. <https://doi.org/10.1016/j.cjtee.2020.02.002>

- Harrison, P. T., Vyse, S., & Huang, P. H. (2019). Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. *Seminars in Cancer Biology*, 61. <https://doi.org/10.1016/j.semcancer.2019.09.015>
- He, J., Huang, Z., Han, L., Gong, Y., & Xie, C. (2021). Mechanisms and management of 3rd-generation EGFR-TKI resistance in advanced non-small cell lung cancer (Review). *International Journal of Oncology*, 59(5). <https://doi.org/10.3892/ijo.2021.5270>
- He, J., Qiu, Z., Fan, J., Xie, X., Sheng, Q., & Sui, X. (2024). Drug tolerant persister cell plasticity in cancer: a revolutionary strategy for more effective anticancer therapies. *Signal Transduction and Targeted Therapy*, 9(1). <https://doi.org/10.1038/s41392-024-01891-4>
- Hendriks, L. E. L., Remon, J., Faivre-Finn, C., Garassino, M. C., Heymach, J. V., Kerr, K. M., Tan, D. S. W., Veronesi, G., & Reck, M. (2024). Non-small-cell lung cancer. *Nature Reviews Disease Primers*, 10(1). <https://doi.org/10.1038/s41572-024-00551-9>
- Hosea, R., Hillary, S., Naqvi, S., Wu, S., & Kasim, V. (2024). The two sides of chromosomal instability: drivers and brakes in cancer. *Signal Transduction and Targeted Therapy*, 9(1). <https://doi.org/10.1038/s41392-024-01767-7>
- Hsieh, M., Choe, J. H., Gadhvi, J., Kim, Y. J., Arguez, M. A., Palmer, M., Gerold, H., Nowak, C., Do, H., Mazambani, S., Knighton, J. K., Cha, M., Goodwin, J., Kang, M. K., Jeong, J. Y., Lee, S. Y., Faubert, B., Xuan, Z., Dale, A. E., ... Kim, J. (2019). p63 and SOX2 Dictate Glucose Reliance and Metabolic Vulnerabilities in Squamous Cell Carcinomas. *Cell Reports*, 28(7), 1860–1878.e9. <https://doi.org/10.1016/j.celrep.2019.07.027>
- Hsu, P.-C., Jablons, D. M., Yang, C.-T., & You, L. (2019). Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC). *International Journal of Molecular Sciences*, 20(15), 3821. <https://doi.org/10.3390/ijms20153821>
- Hu, B., Wiesehöfer, M., Fernando, Liu, Z., Chan, L.-H., Choi, J., Mary Ann Melnick, Anna Arnal Estape, Walther, Z., Zhao, D., Francesc Lopez-Giraldez, Wurtz, A., Cai, G., Fan, R., Gettinger, S., Xiao,

- A., Yan, Q., Homer, R., Nguyen, D. X., & Politi, K. (2024). ASCL1 Drives Tolerance to Osimertinib in *EGFR* Mutant Lung Cancer in Permissive Cellular Contexts. *Cancer Research*, 84(8), 1303–1319. <https://doi.org/10.1158/0008-5472.can-23-0438>
- Huang, A. C.-C., Huang, C.-H., Ju, J.-S., Chiu, T.-H., Tung, P.-H., Wang, C.-C., Liu, C.-Y., Chung, F.-T., Fang, Y.-F., Guo, Y.-K., Kuo, C.-H. S., & Yang, C.-T. (2021). First- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancer. *Therapeutic Advances in Medical Oncology*, 13, 175883592110357–175883592110357. <https://doi.org/10.1177/17588359211035710>
- Huang, L., Guo, Z., Wang, F., & Fu, L. (2021). KRAS mutation: from undruggable to druggable in cancer. *Signal Transduction and Targeted Therapy*, 6(1). <https://doi.org/10.1038/s41392-021-00780-4>
- Imamura, F., Inoue, T., Kunimasa, K., Kubota, A., Kuhara, H., Tamiya, M., Nishino, K., Kimura, M., Kuno, K., Kawachi, H., & Kumagai, T. (2020). Switching from first or Second Generation EGFR-TKI to Osimertinib in *EGFR* Mutation-Positive NSCLC. *Lung Cancer Management*, 9(2). <https://doi.org/10.2217/lmt-2020-0005>
- Isozaki, H., Sakhtemani, R., Abbasi, A., Nikpour, N., Stanzione, M., Oh, S., Langenbucher, A., Monroe, S., Su, W., Cabanos, H. F., Siddiqui, F. M., Phan, N., Jalili, P., Timonina, D., Bilton, S., Gomez-Caraballo, M., Archibald, H. L., Nangia, V., Dionne, K., ... Hata, A. N. (2023). Therapy-induced APOBEC3A drives evolution of persistent cancer cells. *Nature*, 1–9. <https://doi.org/10.1038/s41586-023-06303-1>
- Izumi, M., Costa, D. B., & Kobayashi, S. S. (2024). Targeting of drug-tolerant persister cells as an approach to counter drug resistance in non-small cell lung cancer. *Lung Cancer*, 194, 107885. <https://doi.org/10.1016/j.lungcan.2024.107885>
- Izumi, M., Fujii, M., Kobayashi, I. S., Ho, V., Kashima, Y., Udagawa, H., Costa, D. B., & Kobayashi, S. S. (2024). Integrative single-cell RNA-seq and spatial transcriptomics analyses reveal diverse

- apoptosis-related gene expression profiles in EGFR-mutated lung cancer. *Cell Death & Disease*, 15(8). <https://doi.org/10.1038/s41419-024-06940-y>
- Jiang, Y., Zheng, Y., Zhang, Y.-W., Kong, S., Dong, J., Wang, F., Ziman, B., Gery, S., Hao, J.-J., Zhou, D., Zhou, J., Ho, A. S., Sinha, U. K., Chen, J., Zhang, S., Yin, C., Wei, D.-D., Masaharu Hazawa, Pan, H., ... Jiang, Y.-Y. (2024). Reciprocal inhibition between TP63 and STAT1 regulates anti-tumor immune response through interferon- γ signaling in squamous cancer. *Nature Communications*, 15(1). <https://doi.org/10.1038/s41467-024-46785-9>
- Jiang, Z., Gu, Z., Yu, X., Cheng, T., & Liu, B. (2024). Research progress on the role of bypass activation mechanisms in resistance to tyrosine kinase inhibitors in non-small cell lung cancer. *Frontiers in Oncology*, 14. <https://doi.org/10.3389/fonc.2024.1447678>
- Joshi, A., Butle, A., Hait, S., Mishra, R., Trivedi, V., Thorat, R., Choughule, A., Noronha, V., Prabhash, K., & Dutt, A. (2022). Osimertinib for lung cancer cells harboring low-frequency EGFR T790M mutation. *Translational Oncology*, 22, 101461. <https://doi.org/10.1016/j.tranon.2022.101461>
- Kang, Da H., Lee, J., Im, S., & Chung, C. (2024). Navigating the Complexity of Resistance in Lung Cancer Therapy: Mechanisms, Organoid Models, and Strategies for Overcoming Treatment Failure. *Cancers*, 16(23), 3996. <https://doi.org/10.3390/cancers16233996>
- Kashima, Y., Shibahara, D., Suzuki, A., Muto, K., Kobayashi, I., Plotnick, D., Udagawa, H., Izumi, H., Shibata, Y., Tanaka, K., Fujii, M., Ohashi, A., Seki, M., Goto, K., Tsuchihara, K., Suzuki, Y., & Kobayashi, S. (2021). Single-Cell Analyses Reveal Diverse Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer. *Cancer Research*, 81(18), 4835–4848. <https://doi.org/10.1158/0008-5472.can-20-2811>
- Kathiriya, J. J., Wang, C., Zhou, M., Brumwell, A., Cassandras, M., Le Saux, C. J., Cohen, M., Alysandratos, K.-D., Wang, B., Wolters, P., Matthay, M., Kotton, D. N., Chapman, H. A., & Peng, T. (2022). Human alveolar type 2 epithelium transdifferentiates into metaplastic KRT5+ basal cells. *Nature Cell Biology*, 24(1), 10–23. <https://doi.org/10.1038/s41556-021-00809-4>

- Khaddour, K., Jonna, S., Deneka, A., Patel, J. D., Abazeed, M. E., Golemis, E., Borghaei, H., & Bumber, Y. (2021). Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies. *Cancers*, 13(13), 3164. <https://doi.org/10.3390/cancers13133164>
- Khan, S., Hatton, N., Tough, D., Rintoul, R. C., Pepper, C., Calman, L., McDonald, F., Harris, C., Randle, A., Turner, M. C., Haley, R. A., Rawlinson, J., Crosbie, P. A. J., McCaughan, F., & Hatton, M. (2023). Lung cancer in never smokers (LCINS): development of a UK national research strategy. *BJC Reports*, 1(1), 1–9. <https://doi.org/10.1038/s44276-023-00006-w>
- Khattar, V., Wang, L., & Peng, J.-B. (2022). Calcium selective channel TRPV6: Structure, function, and implications in health and disease. *Gene*, 817, 146192. <https://doi.org/10.1016/j.gene.2022.146192>
- Kim, C., Li, J., Dang, S., Schurmann, P., Dost, A., Moye, A., Paschini, M., Bhetariya, P., Bronson, R., & Sui, S. H. (2023). *Organoid modeling reveals the tumorigenic potential of the alveolar progenitor cell state*. <https://doi.org/10.21203/rs.3.rs-2663901/v1>
- Kobayashi, K., & Tan, A. C. (2023). Unraveling the Impact of Intratumoral Heterogeneity on EGFR Tyrosine Kinase Inhibitor Resistance in EGFR-Mutated NSCLC. *International Journal of Molecular Sciences*, 24(4), 4126. <https://doi.org/10.3390/ijms24044126>
- Kraskowski, O., Stratmann, J. A., Wiesweg, M., Eberhardt, W., Metzenmacher, M., Schmid, K. W., Herold, T., Hans-Ulrich Schildhaus, Darwiche, K., Aigner, C., Stuschke, M., Laue, K., Zaun, G., Kasper, S., Hense, J., Sebastian, M., Schuler, M., & Pogorzelski, M. (2023). Favorable survival outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer sequentially treated with a tyrosine kinase inhibitor and osimertinib in a real-world setting. *Journal of Cancer Research and Clinical Oncology*, 149(11), 9243–9252. <https://doi.org/10.1007/s00432-023-04839-3>
- Krause, A., Roma, L., Lorber, T., Habicht, J., Lardinois, D., Rosaria, M., Prince, S. S., Piscuoglio, S., Ng, C., & Bubendorf, L. (2020). Deciphering the clonal relationship between glandular and

- squamous components in adenosquamous carcinoma of the lung using whole exome sequencing. *Lung Cancer*, 150, 132–138. <https://doi.org/10.1016/j.lungcan.2020.10.013>
- Kunimasa, K., Nagano, T., Shimono, Y., Dokuni, R., Kiri, T., Tokunaga, S., Tamura, D., Yamamoto, M., Tachihara, M., Kobayashi, K., Satouchi, M., & Nishimura, Y. (2017). Glucose metabolism-targeted therapy and withaferin A are effective for epidermal growth factor receptor tyrosine kinase inhibitor-induced drug-tolerant persisters. *Cancer Science*, 108(7), 1368–1377. <https://doi.org/10.1111/cas.13266>
- Kurppa, K. J., Liu, Y., To, C., Zhang, T., Fan, M., Vajdi, A., Knelson, E. H., Xie, Y., Lim, K., Cejas, P., Portell, A., Lizotte, P. H., Ficarro, S. B., Li, S., Chen, T., Haikala, H. M., Wang, H., Bahcall, M., Gao, Y., ... Jänne, P. A. (2020). Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway. *Cancer Cell*, 37(1), 104–122.e12. <https://doi.org/10.1016/j.ccell.2019.12.006>
- Kuśnierz, P. (2023). Genetic differences between smokers and never-smokers with lung cancer. *Frontiers in Immunology*, 14. <https://doi.org/10.3389/fimmu.2023.1063716>
- Lalla, M., Ratnani, A., Yang, J., Wang, M., & Cheng, H. (2026). Drug-Tolerant Persister Cells and Tumor Dormancy in NSCLC: A New Frontier in Overcoming Therapeutic Resistance. *Cancers*, 18(5), 779. <https://doi.org/10.3390/cancers18050779>
- Larasati, Y., Boudou, C., Koval, A., & Katanaev, V. L. (2021). Unlocking the Wnt pathway: Therapeutic potential of selective targeting FZD7 in cancer. *Drug Discovery Today*. <https://doi.org/10.1016/j.drudis.2021.12.008>
- Lau, L. Y. E., Skanderup, A. J., & Tan, A. C. (2025). Lineage Plasticity and Histologic Transformation in EGFR-TKI Resistant Lung Cancer. *International Journal of Molecular Sciences*, 27(1), 445. <https://doi.org/10.3390/ijms27010445>
- Lazzari, C., Gregorc, V., Karachaliou, N., Rosell, R., & Santarpia, M. (2020). Mechanisms of resistance to osimertinib. *Journal of Thoracic Disease*, 12(5), 2851–2858. <https://doi.org/10.21037/jtd.2019.08.30>

- Li, H., Xu, W., Cheng, W., Yu, G., & Tang, D. (2025). Drug-tolerant persister cell in cancer: reversibility, microenvironmental interplay, and therapeutic strategies. *PubMed*, 16, 1612089–1612089. <https://doi.org/10.3389/fphar.2025.1612089>
- Li, L., Wang, Y., Jiao, L., Lin, C., Lu, C., Zhang, K., Hu, C., Ye, J., Zhang, D., Feng, M., & He, Y. (2018). Autophagy determines osimertinib resistance through regulation of stem cell-like properties in EGFR-mutant lung cancer. *bioRxiv (Cold Spring Harbor Laboratory)*. <https://doi.org/10.1101/330092>
- Li, X., Gardner, E. E., MolinaPinelo, S., Wilhelm, C., Mu, P., & QuintanalVillalonga, Á. (2025). Lineage plasticity and histological transformation: tumor histology as a spectrum. *Cell Research*, 35(11), 803–823. <https://doi.org/10.1038/s4142202501180x>
- Li, Y., Mao, T., Wang, J., Zheng, H., Hu, Z., Cao, P., Yang, S., Zhu, L., Guo, S., Zhao, X., Tian, Y., Shen, H., & Lin, F. (2023). Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer. *Cell Communication and Signaling*, 21(1). <https://doi.org/10.1186/s12964-023-01082-8>
- Li, Z., Chu, H., Huang, S., Li, R., Qiu, B., Tan, F., Xue, Q., Gao, S., & He, J. (2024). Risk of treatment-related toxicity from EGFR tyrosine kinase inhibitors: a systematic review and network meta-analysis of randomized clinical trials in EGFR-mutant non-small cell lung cancer. *Journal of Thoracic Disease*, 16(10), 6579–6594. <https://doi.org/10.21037/jtd-24-682>
- Liang, J., Pan, Y., Kong, Z., Wang, B., Yang, J., & Li, J. (2026). Targeting frizzled receptors (FZDs) for anti-tumor therapy: From orthosteric to allosteric inhibition. *Acta Pharmaceutica Sinica B*. <https://doi.org/10.1016/j.apsb.2026.03.046>
- Lim, J. U., Jung, J., Kim, Y. W., Kim, C. Y., Lee, S. H., Park, D. W., Choi, S. I., Ji, W., Yeo, C. D., & Lee, S. H. (2025). Targeting the Tumor Microenvironment in EGFR-Mutant Lung Cancer: Opportunities and Challenges. *Biomedicines*, 13(2), 470–470. <https://doi.org/10.3390/biomedicines13020470>

- Little, D. R., Lynch, A. M., Yan, Y., Akiyama, H., Kimura, S., & Chen, J. (2021). Differential chromatin binding of the lung lineage transcription factor NKX2-1 resolves opposing murine alveolar cell fates in vivo. *Nature Communications*, 12(1). <https://doi.org/10.1038/s41467-021-22817-6>
- Liu, B., Duenas, D., Zheng, L., Reckamp, K., & Shen, B. (2021). Genomic instability as a major mechanism for acquired resistance to EGFR tyrosine kinase inhibitors in cancer. *Protein & Cell*, 13(2), 82–89. <https://doi.org/10.1007/s13238-021-00855-6>
- Liu, S., Jiang, A., Tang, F., Duan, M., & Li, B. (2025). Drug-induced tolerant persists in tumor: mechanism, vulnerability and perspective implication for clinical treatment. *Molecular Cancer*, 24(1). <https://doi.org/10.1186/s12943-025-02323-9>
- Liu, Y., Chen, L., Zhu, X., Zhang, H., & Cao, B. (2025). Real-world prognostic factors for first-line EGFR-TKI efficacy in advanced NSCLC patients harboring EGFR 21 L858R mutation. *Global Medical Genetics*, 12(2), 100051. <https://doi.org/10.1016/j.gmg.2025.100051>
- Liu, Y., Ma, J., Zhang, J., & Sun, Q. (2025). Roles of the WNT/ β -catenin signaling pathway in the metastasis and recurrence of NSCLC. *Advances in Cancer Biology - Metastasis*, 15, 100162. <https://doi.org/10.1016/j.adcanc.2025.100162>
- Loh, C., Koh, W., Ang, J., Lee, W., Chew, W., & Koh, M. (2022). Characteristics of Singapore lung cancer patients who miss out on lung cancer screening recommendations. *Singapore Medical Journal*. <https://doi.org/10.11622/smedj.2022039>
- LoPiccolo, J., Gusev, A., Christiani, D. C., & Jänne, P. A. (2024). Lung cancer in patients who have never smoked — an emerging disease. *Nature Reviews Clinical Oncology*, 21(2), 121–146. <https://doi.org/10.1038/s41571-023-00844-0>
- Luo, W., Zeng, Z., Jin, Y., Yang, L., Fan, T., Wang, Z., Pan, Y., Yang, Y., Yao, M., Li, Y., Xiao, X., Wang, G., Wang, C., Chang, S., Che, G., Zhang, L., Li, Y., Peng, Y., & Li, W. (2023). Distinct immune microenvironment of lung adenocarcinoma in never-smokers from smokers. 4(6), 101078–101078. <https://doi.org/10.1016/j.xcrm.2023.101078>

- Ma, J., Huang, L., & Han, C. (2024). Expert consensus on the use of third-generation EGFR-TKIs in EGFR-mutated advanced non-small cell lung cancer with various T790M mutations post-resistance to first-/second-generation EGFR-TKIs. *Therapeutic Advances in Medical Oncology*, 16. <https://doi.org/10.1177/17588359241289648>
- Marin-Acevedo, J. A., Pellini, B., Kimbrough, E. O., Hicks, J. K., & Chiappori, A. (2023). Treatment Strategies for Non-Small Cell Lung Cancer with Common EGFR Mutations: A Review of the History of EGFR TKIs Approval and Emerging Data. *Cancers*, 15(3), 629. <https://doi.org/10.3390/cancers15030629>
- Marine, J.-C., Dawson, S.-J., & Dawson, M. A. (2020). Non-genetic mechanisms of therapeutic resistance in cancer. *Nature Reviews Cancer*, 20(12), 743–756. <https://doi.org/10.1038/s41568-020-00302-4>
- Marohl, T., Atkins, K. A., Wang, L., & Janes, K. A. (2026). PCSK5M452I Is a Recessive Hypomorph Exclusive to MCF10DCIS.com Cells. *Molecular Cancer Research : MCR*, 24(2), 106–118. <https://doi.org/10.1158/1541-7786.MCR-25-0211>
- Martinez-Marin, D., Stroman, G. C., Fulton, C. J., & Pruitt, K. (2025). Frizzled receptors: gatekeepers of Wnt signaling in development and disease. *Frontiers in Cell and Developmental Biology*, 13. <https://doi.org/10.3389/fcell.2025.1599355>
- Melissaridou, S., Wiechec, E., Magan, M., Jain, M. V., Chung, M. K., Farnebo, L., & Roberg, K. (2019). The effect of 2D and 3D cell cultures on treatment response, EMT profile and stem cell features in head and neck cancer. *Cancer Cell International*, 19(1). <https://doi.org/10.1186/s12935-019-0733-1>
- Meng, F., Li, J., Xia, Z., Wang, Q., Sun, Q., Wang, S., Xu, L., & Yin, R. (2025). Persistent lineage plasticity driving lung cancer development and progression. *Clinical and Translational Medicine*, 15(8). <https://doi.org/10.1002/ctm2.70458>
- Merz, V., Gaule, M., Zecchetto, C., Cavaliere, A., Casalino, S., Pesoni, C., Contarelli, S., Sabbadini, F., Bertolini, M., Mangiameli, D., Milella, M., Fedele, V., & Melisi, D. (2021). Targeting KRAS: The

- Elephant in the Room of Epithelial Cancers. *Frontiers in Oncology*, 11. <https://doi.org/10.3389/fonc.2021.638360>
- Mikubo, M., Inoue, Y., Liu, G., & Tsao, M.-S. (2021). Mechanism of Drug Tolerant Persister Cancer Cells: The Landscape and Clinical Implication for Therapy. *Journal of Thoracic Oncology*, 16(11), 1798–1809. <https://doi.org/10.1016/j.jtho.2021.07.017>
- Mollaoglu, G., Jones, A., Wait, S. J., Mukhopadhyay, A., Jeong, S., Arya, R., Camolotto, S. A., Mosbrugger, T. L., Stubben, C. J., Conley, C. J., Bhutkar, A., Vahrenkamp, J. M., Berrett, K. C., Cessna, M. H., Lane, T. E., Witt, B. L., Salama, M. E., Gertz, J., Jones, K. B., ... Oliver, T. G. (2018). The LineageDefining Transcription Factors SOX2 and NKX21 Determine Lung Cancer Cell Fate and Shape the Tumor Immune Microenvironment. *Immunity*, 49(4), 764–779.e9. <https://doi.org/10.1016/j.immuni.2018.09.020>
- Moreno-Valladares, M., Moncho-Amor, V., Silva, T. M., Garcés, J. P., Álvarez-Satta, M., & Matheu, A. (2023). KRT5⁺/p63⁺ Stem Cells Undergo Senescence in the Human Lung with Pathological Aging. *Aging and Disease*, 14(3), 1013. <https://doi.org/10.14336/ad.2022.1128>
- Morgillo, F., Della Corte, C. M., Fasano, M., & Ciardiello, F. (2016). Mechanisms of resistance to EGFR-targeted drugs: lung cancer. *ESMO Open*, 1(3), e000060. <https://doi.org/10.1136/esmoopen-2016-000060>
- Nicoś, M., Sroka-Bartnicka, A., Kalinka, E., & Krawczyk, P. (2025). Possibilities of Overcoming Resistance to Osimertinib in NSCLC Patients with Mutations in the EGFR Gene. *Cancers*, 17(4), 563–563. <https://doi.org/10.3390/cancers17040563>
- Nie, M., Chen, N., Pang, H., Jiang, T., Jiang, W., Tian, P., Yao, L., Chen, Y., DeBerardinis, R. J., Liu, W., Qin, Y., Zhou, C., & Hu, Z. (2022). Targeting acetylcholine signaling modulates persistent drug tolerance in EGFR-mutant lung cancer and impedes tumor relapse. *Journal of Clinical Investigation*, 132(20). <https://doi.org/10.1172/jci160152>
- Nie, M., & Hu, Z. (2024). Metabolic orchestration of drug-tolerant persister cells in cancer. *Life Medicine*, 3(6). <https://doi.org/10.1093/lifemedi/lnae040>

- Noronha, A., Nataraj, N. B., Lee, J. S., Zhitomirsky, B., Oren, Y., Oster, S., Lindzen, M., Mukherjee, S., Will, R., Ghosh, S., Simoni-Nieves, A., Verma, A., Chatterjee, R., Borgoni, S., Robinson, W., Sinha, S., Brandis, A., Kerr, D. L., Wu, W., ... Yarden, Y. (2022). AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer. *Cancer Discovery*, 12(11), 2666–2683. <https://doi.org/10.1158/2159-8290.cd-22-0111>
- Ohara, S., Suda, K., & Tetsuya Mitsudomi. (2021). *Cell Line Models for Acquired Resistance to First-Line Osimertinib in Lung Cancers—Applications and Limitations*. 10(2), 354–354. <https://doi.org/10.3390/cells10020354>
- Oren, Y., Tsabar, M., Cuoco, M. S., Amir-Zilberstein, L., Cabanos, H. F., Hütter, J.-C., Hu, B., Thakore, P. I., Tabaka, M., Fulco, C. P., Colgan, W., Cuevas, B. M., Hurvitz, S. A., Slamon, D. J., Deik, A., Pierce, K. A., Clish, C., Hata, A. N., Zaganjor, E., ... Regev, A. (2021). Cycling cancer persister cells arise from lineages with distinct programs. *Nature*, 596(7873), 576–582. <https://doi.org/10.1038/s41586-021-03796-6>
- Passaro, A., Malapelle, U., Del Re, M., Attili, I., Russo, A., Guerini-Rocco, E., Fumagalli, C., Pisapia, P., Pepe, F., De Luca, C., Cucchiara, F., Troncone, G., Danesi, R., Spaggiari, L., De Marinis, F., & Rolfo, C. (2020). Understanding EGFR heterogeneity in lung cancer. *ESMO Open*, 5(5), e000919. <https://doi.org/10.1136/esmoopen-2020-000919>
- Pecorari, R., Bernassola, F., Melino, G., & Candi, E. (2022). *Distinct interactors define the p63 transcriptional signature in epithelial development or cancer*. 479(12), 1375–1392. <https://doi.org/10.1042/bcj20210737>
- Pu, Y., Li, L., Peng, H., Liu, L., Heymann, D., Robert, C., Vallette, F. M., & Shen, S. (2023). Drug-tolerant persister cells in cancer: the cutting edges and future directions. *Nature Reviews Clinical Oncology*. <https://doi.org/10.1038/s41571-023-00815-5>
- Pulice, J. L., & Meyerson, M. (2025). Amplified dosage of the NKX2-1 lineage transcription factor controls its oncogenic role in lung adenocarcinoma. *Molecular Cell*. <https://doi.org/10.1016/j.molcel.2025.03.001>

- Punzi, S., Cittaro, D., Gatti, G., Crupi, G., Botrugno, O. A., Cartalemi, A. A., Gutfreund, A., Oneto, C., Giansanti, V., Battistini, C., Santacatterina, G., Patruno, L., Villanti, I., Palumbo, M., Lavery, D. J., Giannese, F., Graudenzi, A., Caravagna, G., Antoniotti, M., ... Tonon, G. (2025). Early tolerance and late persistence as alternative drug responses in cancer. *Nature Communications*, 16(1). <https://doi.org/10.1038/s41467-024-54728-7>
- Pérez-González, A., Bévart, K., & Blanpain, C. (2023). Cancer cell plasticity during tumor progression, metastasis and response to therapy. *Nature Cancer*, 4(8), 1063–1082. <https://doi.org/10.1038/s43018-023-00595-y>
- Qin, K., Hong, L., Zhang, J., & Le, X. (2023). MET Amplification as a Resistance Driver to TKI Therapies in Lung Cancer: Clinical Challenges and Opportunities. *Cancers*, 15(3), 612–612. <https://doi.org/10.3390/cancers15030612>
- Qin, S., Jiang, J., Lu, Y., Nice, E. C., Huang, C., Zhang, J., & He, W. (2020). Emerging role of tumor cell plasticity in modifying therapeutic response. *Signal Transduction and Targeted Therapy*, 5(1), 1–36. <https://doi.org/10.1038/s41392-020-00313-5>
- Quintanal-Villalonga, A., Taniguchi, H., Zhan, Y. A., Hasan, M. M., Chavan, S. S., Meng, F., Uddin, F., Allaj, V., Manoj, P., Shah, N. S., Chan, J. M., Ciampricotti, M., Chow, A., Offin, M., Ray-Kirton, J., Egger, J. D., Bhanot, U. K., Linkov, I., Asher, M., ... Rudin, C. M. (2021). Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation. *Journal of Hematology & Oncology*, 14(1). <https://doi.org/10.1186/s13045-021-01186-z>
- Quintanal-Villalonga, Á., Chan, J. M., Yu, H. A., Pe'er, D., Sawyers, C. L., Sen, T., & Rudin, C. M. (2020). Lineage plasticity in cancer: a shared pathway of therapeutic resistance. *Nature Reviews Clinical Oncology*, 17(6), 360–371. <https://doi.org/10.1038/s41571-020-0340-z>
- Rakhade, S., Chen, M. F., Quintanal-Villalonga, A., Sabet, A., Manoj, P., Chaudhary, O., Xu, T., Masilionis, I., Falcon, C. J., Egger, J. V., Nawy, T., Mazutis, L., Chaligne, R., Yu, H. A., Pe'er, D., Rudin, C. M., & Chan, J. M. (2024). Signatures of early plasticity in the histological

- transformation of lung cancer. *Journal of Clinical Oncology*, 42(16_suppl), 8042–8042.
https://doi.org/10.1200/jco.2024.42.16_suppl.8042
- Ramisetty, S., Kulkarni, P., Bhattacharya, S., Nam, A., Singhal, S. S., Guo, L., Mirzapioazova, T., Mambetsariev, B., Mittan, S., Malhotra, J., Pisick, E., Subbiah, S., Rajurkar, S., Massarelli, E., Salgia, R., & Mohanty, A. (2023). A Systems Biology Approach for Addressing Cisplatin Resistance in Non-Small Cell Lung Cancer. *Journal of Clinical Medicine*, 12(2), 599.
<https://doi.org/10.3390/jcm12020599>
- Ren, S., Zhu, J., Shan, G., Liang, J., Bian, Y., Lin, H., Shi, H., Pan, B., Zhao, G., Yang, H., Huang, X., Zhan, C., Ge, Di, & Bi, G. (2025). Transcription factor ZNF266 suppresses cancer progression by modulating CA9-mediated intracellular pH alteration in lung adenocarcinoma. *Respiratory Research*, 26(1). <https://doi.org/10.1186/s12931-025-03278-7>
- Rosell, R., Cardona, A. F., Arrieta, O., Aguilar, A., Ito, M., Pedraz, C., Codony-Servat, J., & Santarpia, M. (2021). Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities. *British Journal of Cancer*, 125(12), 1602–1611.
<https://doi.org/10.1038/s41416-021-01519-2>
- Rotow, J. K., Lee, J. K., Madison, R. W., Oxnard, G. R., Jänne, P. A., & Schrock, A. B. (2024). Real-World Genomic Profile of EGFR Second-Site Mutations and Other Osimertinib Resistance Mechanisms and Clinical Landscape of NSCLC Post-Osimertinib. *Journal of Thoracic Oncology*, 19(2), 227–239. <https://doi.org/10.1016/j.jtho.2023.09.1453>
- Rusak, A., Kątnik, E., Tomasz Górnicki, Schmuttermayr, C., Kujawa, K., Aleksandra Piotrowska, Katarzyna Ratajczak-Wielgomas, Kmiecik, A., Wojnar, A., Piotr Dzięgiel, & Kzhyshkowska, J. (2024). New insights into the role of the CHI3L2 protein in invasive ductal breast carcinoma. *Scientific Reports*, 14(1). <https://doi.org/10.1038/s41598-024-77930-5>
- Russo, M. (2024). Genetic and non-genetic drug resistance: Darwin or Lamarck? *Molecular Oncology*, 18(2), 241–244. <https://doi.org/10.1002/1878-0261.13601>

- Russo, M., Chen, M., Mariella, E., Peng, H., Rehman, S. K., Sancho, E., Sogari, A., Toh, T. S., Balaban, N. Q., Batlle, E., Bernards, R., Garnett, M. J., Hangauer, M., Leucci, E., Marine, J.-C., O'Brien, C. A., Oren, Y., E. Elizabeth Patton, Robert, C., ... Bardelli, A. (2024). Cancer drug-tolerant persister cells: from biological questions to clinical opportunities. *Nature Reviews. Cancer*. <https://doi.org/10.1038/s41568-024-00737-z>
- Ruyseveldt, E., Martens, K., & Steelant, B. (2021). Airway Basal Cells, Protectors of Epithelial Walls in Health and Respiratory Diseases. *Frontiers in Allergy*, 2. <https://doi.org/10.3389/falgy.2021.787128>
- Sachs, N., Papaspyropoulos, A., Zomer-van Ommen, D. D., Heo, I., Böttinger, L., Klay, D., Weeber, F., Huelsz-Prince, G., Iakobachvili, N., Amatngalim, G. D., de Ligt, J., van Hoeck, A., Proost, N., Viveen, M. C., Lyubimova, A., Teeven, L., Derakhshan, S., Korving, J., Begthel, H., ... Clevers, H. (2019). Long-term expanding human airway organoids for disease modeling. *The EMBO Journal*, 38(4). <https://doi.org/10.15252/embj.2018100300>
- Scheiblecker, L., Kollmann, K., & Sexl, V. (2020). CDK4/6 and MAPK—Crosstalk as Opportunity for Cancer Treatment. *Pharmaceuticals*, 13(12), 418. <https://doi.org/10.3390/ph13120418>
- Schmid, S., Li, J. J. N., & Leighl, N. B. (2020). Mechanisms of osimertinib resistance and emerging treatment options. *Lung Cancer*, 147, 123–129. <https://doi.org/10.1016/j.lungcan.2020.07.014>
- Schoenfeld, A. J., Chan, J., Kubota, D., Sato, H., Rizvi, H., Daneshbod, Y., Chang, J. S., Paik, P. K., Offin, M., Arcila, M. E., Davare, M. A., Shinde, U., Pe'er, D., Rekhtman, N., Kris, M. G., Somwar, R., Riely, G. J., Ladanyi, M., & Yu, H. A. (2020). Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer. 26(11), 2654–2663. <https://doi.org/10.1158/1078-0432.ccr-19-3563>
- Schoenfeld, A. J., & Yu, H. A. (2020). The Evolving Landscape of Resistance to Osimertinib. *Journal of Thoracic Oncology*, 15(1), 18–21. <https://doi.org/10.1016/j.jtho.2019.11.005>

- Senft, D. (2023). AT1 cells appear centre stage. *Nature Reviews Cancer*, 23(10), 652–652. <https://doi.org/10.1038/s41568-023-00618-x>
- Shah, R., & Lester, J. F. (2020). Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non–Small-Cell Lung Cancer: a Clash of the Generations. *Clinical Lung Cancer*, 21(3). <https://doi.org/10.1016/j.clc.2019.12.003>
- Shaurova, T., Zhang, L., Goodrich, D. W., & Hershberger, P. A. (2020). Understanding Lineage Plasticity as a Path to Targeted Therapy Failure in EGFR-Mutant Non-small Cell Lung Cancer. *Frontiers in Genetics*, 11. <https://doi.org/10.3389/fgene.2020.00281>
- Shen, S., Vagner, S., & Robert, C. (2020). Persistent Cancer Cells: The Deadly Survivors. *Cell*, 183(4), 860–874. <https://doi.org/10.1016/j.cell.2020.10.027>
- Shi, R., Radulovich, N., Ng, C., Liu, N., Notsuda, H., Cabanero, M., Martins-Filho, S. N., Raghavan, V., Li, Q., Mer, A. S., Rosen, J. C., Li, M., Wang, Y.-H., Tamblyn, L., Pham, N.-A., Haibe-Kains, B., Liu, G., Moghal, N., & Tsao, M.-S. (2020). Organoid Cultures as Preclinical Models of Non–Small Cell Lung Cancer. *Clinical Cancer Research*, 26(5), 1162–1174. <https://doi.org/10.1158/1078-0432.ccr-19-1376>
- Shinozaki, T., Togasaki, K., Hamamoto, J., Mitsuishi, A., Fukushima, T., Sugihara, K., Ebisudani, T., Okada, M., Saito, A., Shigematsu, L., Takaoka, H., Ito, F., Ohgino, K., Ishioka, K., Watanabe, K., Hishima, T., Kurebayashi, Y., Emoto, K., Terai, H., ... Sato, T. (2025). Basal-shift transformation leads to EGFR therapy-resistance in human lung adenocarcinoma. *Nature Communications*, 16(1). <https://doi.org/10.1038/s41467-025-59623-3>
- Sompel, K., Elango, A., Smith, A. J., & Tennis, M. A. (2021). Cancer chemoprevention through Frizzled receptors and EMT. *Discover Oncology*, 12(1). <https://doi.org/10.1007/s12672-021-00429-2>
- Su, P.-L., Furuya, N., Asrar, A., Rolfo, C., Li, Z., Carbone, D. P., & He, K. (2025). Recent advances in therapeutic strategies for non-small cell lung cancer. *Journal of Hematology & Oncology*, 18(1). <https://doi.org/10.1186/s13045-025-01679-1>

- Su, Y., Ko, M. E., Cheng, H., Zhu, R., Xue, M., Wang, J., Lee, J. W., Frankiw, L., Xu, A., Wong, S., Robert, L., Takata, K., Yuan, D., Lu, Y., Huang, S., Ribas, A., Levine, R., Nolan, G. P., Wei, W., ... Heath, J. R. (2020). Multi-omic single-cell snapshots reveal multiple independent trajectories to drug tolerance in a melanoma cell line. *Nature Communications*, 11(1). <https://doi.org/10.1038/s41467-020-15956-9>
- Subbalakshmi, A. R., Ramisetty, S., Mohanty, A., Pareek, S., Do, D., Shrestha, S., Khan, A., Talwar, N., Tan, T., Vishnubhotla, P., Singhal, S. S., Salgia, R., & Kulkarni, P. (2024). Phenotypic Plasticity and Cancer: A System Biology Perspective. *Journal of Clinical Medicine*, 13(15), 4302. <https://doi.org/10.3390/jcm13154302>
- Swayden, M., Chhouri, H., Anouar, Y., & Grumolato, L. (2020). Tolerant/Persister Cancer Cells and the Path to Resistance to Targeted Therapy. *Cells*, 9(12), 2601. <https://doi.org/10.3390/cells9122601>
- Takahashi, H., Sakakibara-Konishi, J., Furuta, M., Shoji, T., Tsuji, K., Morinaga, D., Kikuchi, E., Kikuchi, J., Noguchi, T., Hatanaka, K. C., Hatanaka, Y., Shinagawa, N., & Konno, S. (2022). Notch pathway regulates osimertinib drug-tolerant persistence in EGFR-mutated non-small-cell lung cancer. *Cancer Science*, 114(4), 1635–1650. <https://doi.org/10.1111/cas.15674>
- Takeyasu, Y., Yoshida, T., Masuda, K., Matsumoto, Y., Shinno, Y., Okuma, Y., Goto, Y., Horinouchi, H., Yamamoto, N., & Ohe, Y. (2024). Distinct Progression and Efficacy of First-Line Osimertinib Treatment According to Mutation Subtypes in Metastatic NSCLC Harboring EGFR Mutations. *JTO Clinical and Research Reports*, 5(2), 100636. <https://doi.org/10.1016/j.jtocrr.2024.100636>
- Tamellini, E., Frusteri, C., & Ferrarini, I. (2025). Genes-first and phenotypes-first paths to treatment resistance in hematological malignancies. *Cell Death and Disease*, 16(1), 819–819. <https://doi.org/10.1038/s41419-025-08127-5>
- Tan, A. C., & Tan, D. S. W. (2022). Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, 40(6), 611–625. <https://doi.org/10.1200/JCO.21.01626>

- Tang, S., Xue, Y., Qin, Z., Fang, Z., Sun, Y., Yuan, C., Pan, Y., Zhao, Y., Tong, X., Zhang, J., Huang, H., Chen, Y., Hu, L., Huang, D., Wang, R., Zou, W., Li, Y., Thomas, R. K., Ventura, A., ... Ji, H. (2023). Counteracting lineage-specific transcription factor network finely tunes lung adeno-to-squamous transdifferentiation through remodeling tumor immune microenvironment. *National Science Review*, 10, 4. <https://doi.org/10.1093/nsr/nwad028>
- Tang, Y., Zang, H., Wen, Q., & Fan, S. (2023). *AXL in cancer: a modulator of drug resistance and therapeutic target*. 42(1). <https://doi.org/10.1186/s13046-023-02726-w>
- Tian, Y., Bhattacharya, R., Yoo, S., Jiang, F., Park, E., Granados, G. L., Shen, Y., Park, K.-S., Kaniskan, H. U., Jin, J., Hopkins, B. D, Zhu, J., & Watanabe, H. (2025). Epigenomic Analysis Identifies DTP Subpopulation Using HOPX to Develop Targeted Therapy Resistance in Lung Adenocarcinoma. *iScience*, 112387–112387. <https://doi.org/10.1016/j.isci.2025.112387>
- Tito, C., Masciarelli, S., Colotti, G., & Fazi, F. (2025). EGF receptor in organ development, tissue homeostasis and regeneration. *Journal of Biomedical Science*, 32(1). <https://doi.org/10.1186/s12929-025-01119-9>
- Torasawa, M., Yoshida, T., Shiraishi, K., Yagishita, S., Ono, H., Uehara, Y., Miyakoshi, J., Tateishi, A., Igawa, Y. S., Higashiyama, R. I., Mochizuki, A., Masuda, K., Matsumoto, Y., Shinno, Y., Okuma, Y., Goto, Y., Horinouchi, H., Hamamoto, R., Yamamoto, N., ... Ohe, Y. (2025). Implications of EGFR expression on EGFR signaling dependency and adaptive immunity against EGFR-mutated lung adenocarcinoma. *Lung Cancer*, 202, 108494. <https://doi.org/10.1016/j.lungcan.2025.108494>
- Toth, A., Kannan, P., Snowball, J., Kofron, M., Wayman, J. A., Bridges, J. P., Miraldi, E. R., Swarr, D., & Zacharias, W. J. (2023). Alveolar epithelial progenitor cells require Nkx2-1 to maintain progenitor-specific epigenomic state during lung homeostasis and regeneration. *Nature Communications*, 14(1), 8452. <https://doi.org/10.1038/s41467-023-44184-0>
- Triphuridet, N., Nagasaka, M., Shum, E., & Ou, S.-H. I. (2024). Race, age at diagnosis and histological characteristics of lung cancer in never-smokers (LCINS) and ever-smokers in low-dose

- computed tomography (LDCT) screening: a systematic review and meta-analysis. *Translational Lung Cancer Research*, 13(5), 1047–1060. <https://doi.org/10.21037/tlcr-23-816>
- Triphuridet, N., Zhang, S., Nagasaka, M., Gao, Y., Zhao, J. J., Syn, N., Hanaoka, T., Ou, S. H. I., & Shum, E. (2023). Low-Dose Computed Tomography (LDCT) Lung Cancer Screening in Asian Female Never-Smokers Is as Efficacious in Detecting Lung Cancer as in Asian Male Ever-Smokers: A Systematic Review and Meta-Analysis. *Journal of Thoracic Oncology*, 18(6), 698–717. <https://doi.org/10.1016/j.jtho.2023.01.094>
- Tsuji, T., Ozasa, H., Aoki, W., Aburaya, S., Funazo, T. Y., Furugaki, K., Yoshimura, Y., Yamazoe, M., Ajimizu, H., Yasuda, Y., Nomizo, T., Yoshida, H., Sakamori, Y., Wake, H., Ueda, M., Kim, Y. H., & Hirai, T. (2020). YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation. *Nature Communications*, 11(1). <https://doi.org/10.1038/s41467-019-13771-5>
- Tyner, J. W., Haderk, F., Kumaraswamy, A., Baughn, L. B., Van Ness, B., Liu, S., Marathe, H., Alumkal, J. J., Bivona, T. G., Chan, K. S., Druker, B. J., Hutson, A. D., Nelson, P. S., Sawyers, C. L., & Willey, C. D. (2022). Understanding Drug Sensitivity and Tackling Resistance in Cancer. *Cancer Research*, 82(8), 1448–1460. <https://doi.org/10.1158/0008-5472.can-21-3695>
- Uniyal, P., Kashyap, V. K., Behl, T., Parashar, D., & Rawat, R. (2025). KRAS Mutations in Cancer: Understanding Signaling Pathways to Immune Regulation and the Potential of Immunotherapy. *Cancers*, 17(5), 785–785. <https://doi.org/10.3390/cancers17050785>
- Vaid, A., Gupta, A., & Momi, G. (2021). Overall survival in stage IV EGFR mutation-positive NSCLC: Comparing first-, second- and third-generation EGFR-TKIs (Review). *International Journal of Oncology*, 58(2), 171–184. <https://doi.org/10.3892/ijo.2021.5168>
- Vazquez-Armendariz, A. I., & Tata, P. R. (2023). Recent advances in lung organoid development and applications in disease modeling. *Journal of Clinical Investigation*, 133(22). <https://doi.org/10.1172/jci170500>

- Wang, H., Tang, S., Wu, Q., He, Y., Zhu, W., Xie, X., Qin, Z., Wang, X., Zhou, S., Yao, S., Xu, X., Guo, C., Tong, X., Han, S., Chou, Y.-H., Wang, Y., Wong, K.-K., Yang, C.-G., Chen, L., Hu, L., et al. (2024). Integrative study of lung cancer adeno-to-squamous transition in EGFR TKI resistance identifies RAPGEF3 as a therapeutic target. *National Science Review*, 11(12). <https://doi.org/10.1093/nsr/nwae392>
- Wang, J., Guo, C., Wang, J., Zhang, X., Qi, J., Huang, X., Hu, Z., Wang, H., & Hong, B. (2025). Tumor Mutation Signature Reveals the Risk Factors of Lung Adenocarcinoma with *EGFR* or *KRAS* Mutation. *Cancer Control*, 32. <https://doi.org/10.1177/10732748241307363>
- Wang, L., Wei, D., Li, S., & Jiang, S. (2025). Advances in biomarkers of resistance to KRAS mutation-targeted inhibitors. *Discover Oncology*, 16(1). <https://doi.org/10.1007/s12672-025-03569-x>
- Wang, P., Ke, B., & Ma, G. (2024). Drug-tolerant persister cancer cells. *Journal of the National Cancer Center*, 4(1), 1–5. <https://doi.org/10.1016/j.jncc.2023.12.002>
- Wang, P., Sun, S., Lam, S., & Lockwood, W. W. (2023). New insights into the biology and development of lung cancer in never smokers—implications for early detection and treatment. *Journal of Translational Medicine*, 21(1). <https://doi.org/10.1186/s12967-023-04430-x>
- Wang, R., Yamada, T., Kita, K., Taniguchi, H., Arai, S., Fukuda, K., Terashima, M., Ishimura, A., Nishiyama, A., Tanimoto, A., Takeuchi, S., Ohtsubo, K., Yamashita, K., Yamano, T., Yoshimura, A., Takayama, K., Kaira, K., Taniguchi, Y., Atagi, S., ... Yano, S. (2020). Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer. *Nature Communications*, 11(1). <https://doi.org/10.1038/s41467-020-18442-4>
- Warnecke, B., & Nagasaka, M. (2024). Beyond First-Line Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitors (TKI): Approach to Resistance. *Advances in Oncology*, 4(1), 63–72. <https://doi.org/10.1016/j.yao.2024.01.008>

- Wirth, D., Özdemir, E., & Hristova, K. (2023). Quantification of ligand and mutation-induced bias in EGFR phosphorylation in direct response to ligand binding. *Nature Communications*, 14(1), 1–13. <https://doi.org/10.1038/s41467-023-42926-8>
- Wu, F., Fan, J., He, Y., Xiong, A., Yu, J., Li, Y., Zhang, Y., Zhao, W., Zhou, F., Li, W., Zhang, J., Zhang, X., Qiao, M., Gao, G., Chen, S., Chen, X., Li, X., Hou, L., Wu, C., ... Zhou, C. (2021). Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer. *Nature Communications*, 12(1), 2540. <https://doi.org/10.1038/s41467-021-22801-0>
- Wu, L., Ke, L., Zhang, Z., Yu, J., & Meng, X. (2020). Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors. *Frontiers in Oncology*, 10. <https://doi.org/10.3389/fonc.2020.602762>
- Xiao, X., Xu, R., Lu, J., Xin, B., Wang, C., Zhu, K., Zhang, H., & Chen, X. (2024). The potential role of next-generation sequencing in identifying MET amplification and disclosing resistance mechanisms in NSCLC patients with osimertinib resistance. *Frontiers in Oncology*, 14. <https://doi.org/10.3389/fonc.2024.1470827>
- Yadav, M., Sharma, A., Ketki Patne, Saba Tabasum, Jyoti Suryavanshi, Rawat, L., Machaalani, M., Eid, M., Singh, R. P., Choueiri, T. K., Pal, S., & Akash Sabarwal. (2025). AXL signaling in cancer: from molecular insights to targeted therapies. *Signal Transduction and Targeted Therapy*, 10(1). <https://doi.org/10.1038/s41392-024-02121-7>
- Yan, M., Wang, W., Zhou, J., Chang, M., Peng, W., Zhang, G., Li, J., Li, H., & Bai, C. (2020). Knockdown of PLAT enhances the anticancer effect of gefitinib in non-small cell lung cancer. *Journal of Thoracic Disease*, 12(3), 712–723. <https://doi.org/10.21037/jtd.2019.12.106>
- Yang, F., Li, Y., Liu, B., You, J., & Zhou, Q. (2018). Cancer stem cell-like population is preferentially suppressed by EGFR-TKIs in EGFR-mutated PC-9 tumor models. *Experimental Cell Research*, 362(1), 195–202. <https://doi.org/10.1016/j.yexcr.2017.11.017>

- Yang, J., Li, Y., Huang, Y., Chen, H., & Sui, P. (2024). Unlocking lung regeneration: insights into progenitor cell dynamics and metabolic control. *Cell Regeneration*, 13(1). <https://doi.org/10.1186/s13619-024-00212-y>
- Yang, M., Shen, H., Flodby, P., Koss, M., Bassiouni, R., Liu, Y., Stueve, T. R., Mullen, D. J., Ryan, A. L., Jashashvili, T., Carpten, J., Castaldi, A., Wallace, W. D., Zhou, B., Borok, Z., & Marconett, C. N. (2023). Abstract 5: Alveolar epithelial type 1 cells can serve as a cell of origin for lung adenocarcinoma with distinct molecular and phenotypic presentation. *Cancer Research*, 83(7_Supplement), 5–5. <https://doi.org/10.1158/1538-7445.am2023-5>
- Yang, M., Shen, H., Flodby, P., Koss, M. D., Bassiouni, R., Liu, Y., Jashashvili, T., Stueve, T. R., Mullen, D. J., Ryan, A. L., Carpten, J., Castaldi, A., Wallace, W. D., Zhou, B., Borok, Z., & Marconett, C. N. (2022). *Alveolar epithelial type 1 cells serve as a cell of origin for lung adenocarcinoma with distinct molecular and phenotypic presentation*. <https://doi.org/10.1101/2022.10.29.514334>
- Yin, L., Gao, X., Ni, C., Zhao, B., & Cheng, X. (2023). The application of patient-derived organoid in the research of lung cancer. *Cellular Oncology*, 46(3), 503–519. <https://doi.org/10.1007/s13402-023-00771-3>
- Zaman, A., & Bivona, T. G. (2021). Targeting AXL in NSCLC. *Lung Cancer: Targets and Therapy, Volume 12*, 67–79. <https://doi.org/10.2147/lctt.s305484>
- Zatzman, M., Quintanal-Villalonga, A., Salehi, S., Ceglia, N., Lee, J. J.-K., Pupo, A. N., Falcon, C. J., Rusk, N., Masilionis, I., Chaudhary, O., Manoj, P., Chaligne, R., McPherson, A., Rudin, C. M., Shah, S. P., & Yu, H. A. (2025). *Complementary modes of resistance to EGFR TKI in lung adenocarcinoma through MAPK activation and cellular plasticity*. <https://doi.org/10.1101/2025.05.07.652714>
- Zhang, J., Vokes, N., Li, M., Xu, J., Bai, H., Wang, J., Wang, Z., & Zhang, J. (2024). Overcoming EGFR-TKI resistance by targeting the tumor microenvironment. *Chinese Medical Journal Pulmonary and Critical Care Medicine*, 2(3), 151–161. <https://doi.org/10.1016/j.pccm.2024.08.002>

- Zhao, J., Li, M., Niu, L., Zhao, Y., & Song, X. (2025). Lung cancer in non-smoking women (LCINSW): from risk factors to precision therapy. *Cancer and Metastasis Reviews*, 44(4).
<https://doi.org/10.1007/s10555-025-10289-9>
- Zhao, R., Xu, Y., Chen, Y., Zhang, J., Teng, F., Liao, S., Chen, S., Wu, Q., Xiang, C., Pang, J., Shang, Z., Zhao, J., Bao, H., Bao, H., Shao, Y., Lu, S., & Han, Y. (2023). Clonal dynamics and Stereoseq resolve origin and phenotypic plasticity of adenosquamous carcinoma. *Npj Precision Oncology*, 7(1), 80. <https://doi.org/10.1038/s41698023004308>
- Zheng, H., Xue, H., Zhang, C., Shi, K., & Zhang, R. (2022). The roles of BTG1 mRNA expression in cancers: A bioinformatics analysis. *Frontiers in Genetics*, 13.
<https://doi.org/10.3389/fgene.2022.1006636>
- Zhou, D., Zhang, J., Deng, X., Lu, X., Liu, X., Yu, J., Zheng, H., & Dai, J. (2025). SUSD2 hypersialylation promotes early lung adenocarcinoma progression by driving ECM remodeling and pro-tumorigenic fibroblast activation. *Cancer Letters*, 633, 217995.
<https://doi.org/10.1016/j.canlet.2025.217995>
- Zhou, M., Haga, Y., Nishimura, A., Tanahashi, S., Higashisaka, K., & Tsutsumi, Y. (2025). Cell cycle dynamics analysis of drug-tolerant persister cells in non-small cell lung cancer. *Biochemical and Biophysical Research Communications*, 775, 152107.
<https://doi.org/10.1016/j.bbrc.2025.152107>
- Zhou, X., Ji, Y., & Zhou, J. (2023). *Multiple Strategies to Develop Small Molecular KRAS Directly Bound Inhibitors*. 28(8), 3615–3615. <https://doi.org/10.3390/molecules28083615>
- Zhou, X., Zeng, L., Huang, Z., Ruan, Z., Yan, H., Zou, C., Xu, S., & Zhang, Y. (2025). Strategies Beyond 3rd EGFR-TKI Acquired Resistance: Opportunities and Challenges. *Cancer Medicine*, 14(9).
<https://doi.org/10.1002/cam4.70921>